<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Phentolamine (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Phentolamine (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Phentolamine (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="142990" href="/d/html/142990.html" rel="external">see "Phentolamine (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="143013" href="/d/html/143013.html" rel="external">see "Phentolamine (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58720870"><span class="drugH1">Brand Names: US</span>
<ul>
<li>OraVerse</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F58720953"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>OraVerse;</li>
<li>Rogitine</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F58721539"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Alpha<sub>1</sub> Blocker</span>;</li>
<li>
<span class="list-set-name">Antidote, Extravasation</span>;</li>
<li>
<span class="list-set-name">Antihypertensive</span></li></ul></div>
<div class="block don drugH1Div" id="F58720955"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e015773b-9bea-4d13-893e-a214e2875f39">Extravasation of sympathomimetic vasopressors, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation of sympathomimetic vasopressors (eg, dopamine, epinephrine, norepinephrine, phenylephrine), treatment:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: SUBQ: Infiltrate area of extravasation with a small amount (eg, 1 mL given in 0.1 to 0.2 mL aliquots) of a 0.5 mg/mL solution within 12 hours of extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8414723','lexi-content-ref-34158148','lexi-content-ref-3659173','lexi-content-ref-11536027','lexi-content-ref-18069429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8414723','lexi-content-ref-34158148','lexi-content-ref-3659173','lexi-content-ref-11536027','lexi-content-ref-18069429'])">Ref</a></span>); concentrations up to 1 mg/mL have been used in infants and have also been suggested in neonates although data is very limited and based on clinical experience and institutional protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Beall.1','lexi-content-ref-1720079','lexi-content-ref-6628223','lexi-content-ref-10532013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Beall.1','lexi-content-ref-1720079','lexi-content-ref-6628223','lexi-content-ref-10532013'])">Ref</a></span>). Total dose required depends on the size of extravasation; dose may be repeated if required. One case report administered a total of 7.5 mL of a 0.5 mg/mL solution to a 2-day-old, 37 week GA neonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3659173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3659173'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F58720917"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6483b8e6-3265-4d55-af82-bc68fd7aa300">Diagnosis of pheochromocytoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnosis of pheochromocytoma (phentolamine blocking test): Note:</b> The phentolamine-blocking test for the diagnosis of pheochromocytoma has largely been supplanted by the measurement of catecholamine concentrations and catecholamine metabolites (eg, metanephrine) in the plasma and urine; reserve phentolamine for cases when additional confirmation is necessary to determine diagnosis.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">IM: 3 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 1 mg.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e015773b-9bea-4d13-893e-a214e2875f39">Extravasation of sympathomimetic vasopressors, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation of sympathomimetic vasopressors (eg, dopamine, epinephrine, norepinephrine, phenylephrine), treatment:</b> Limited data available for infants:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: SUBQ: Infiltrate area of extravasation with a small amount (eg, 1 mL given in 0.2 mL aliquots) of a 0.5 to 1 mg/mL solution within 12 hours of extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8414723','lexi-content-ref-34158148','lexi-content-ref-1720079','lexi-content-ref-6628223','lexi-content-ref-10532013','lexi-content-ref-Park.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8414723','lexi-content-ref-34158148','lexi-content-ref-1720079','lexi-content-ref-6628223','lexi-content-ref-10532013','lexi-content-ref-Park.1','lexi-content-ref-Manu.1'])">Ref</a></span>). Total dose required depends on the size of extravasation; dose may be repeated if required. When reported, the total dose needed was 1 to 5 mL of a 1 mg/mL solution; however, other concentrations could be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10532013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10532013'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f9b59f90-77ee-47b5-9963-f1e26596c253">Hypertensive episodes associated with pheochromocytoma, prevention and treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertensive episodes associated with pheochromocytoma, prevention and treatment: Note:</b> In the perioperative period, the use of other agents may be preferred due to slow onset of action and prolonged duration of phentolamine in comparison to the other agents (eg, nitroprusside) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kiefer.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kiefer.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Preoperative:</i> Children and Adolescents: IM, IV: 1 mg given 1 to 2 hours before surgery and repeat if needed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Intraoperative:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Manufacturer's labeling: Children and Adolescents: IV: 1 mg as indicated to prevent or control paroxysms of hypertension, tachycardia, respiratory depression, seizure, or other effects associated with epinephrine intoxication resulting from tumor manipulation.</p>
<p style="text-indent:-2em;margin-left:6em;">Alternate dosing: Limited data available: Infants, Children, and Adolescents: IV, IM: 0.05 to 0.1 mg/kg/dose, repeated every 5 minutes until hypertension is controlled, then every 2 to 4 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.1','lexi-content-ref-Schure.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.1','lexi-content-ref-Schure.1'])">Ref</a></span>). <b>Note:</b> Usual adult dose is 5 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fdd77cbe-dfa4-4ca2-9cdb-d3a6d7a1b274">Reversal of oral soft tissue anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of oral soft tissue (lip, tongue) anesthesia (OraVerse): Note:</b> Dose is based upon the number of cartridge(s) of local anesthetic administered; location and administration technique (infiltration or block injection) should be the same as used for local anesthetic administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years weighing ≥15 kg and Adolescents: Submucosal oral injection: Infiltration or block technique:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>Amount of Local Anesthetic Administered</b></p></td>
<td align="center">
<p style="text-indent:0em;">
<b>Dose of OraVerse</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<sup>1</sup>/<sub>4</sub> cartridge</p></td>
<td align="center">
<p style="text-indent:0em;">
<sup>1</sup>/<sub>4</sub> cartridge (0.1 mg)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<sup>1</sup>/<sub>2</sub> cartridge</p></td>
<td align="center">
<p style="text-indent:0em;">
<sup>1</sup>/<sub>2</sub> cartridge (0.2 mg)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1 cartridge</p></td>
<td align="center">
<p style="text-indent:0em;">1 cartridge (0.4 mg)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">2 cartridges</p></td>
<td align="center">
<p style="text-indent:0em;">2 cartridges (0.8 mg)</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Maximum dose:</p>
<p style="text-indent:-2em;margin-left:8em;">15 to &lt;30 kg: 0.2 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">≥30 kg: 0.8 mg/dose. <b>Note:</b> A dose of &gt;0.4 mg has not been studied in children &lt;4 years of age.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F58720855"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F58720853"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F58720916"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="142990" href="/d/html/142990.html" rel="external">see "Phentolamine (systemic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8667e1b9-2734-457c-8869-4e8966019b6d">Extravasation of vasopressors, management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation of vasopressors, management:</b>
<b>Note:</b> Most accidental vasopressor extravasations can be managed without pharmacologic treatment; may consider in patients with refractory pain and tissue ischemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>)<i>.</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Peripheral extravasation of norepinephrine (labeled use) and other sympathomimetic vasopressors (off-label use), management: </i>Local infiltration injection: <b>SUBQ</b>: 5 to 10 mg (diluted in 10 mL NS) divided into multiple <b>SUBQ </b>injections along the area of extravasation; if IV catheter remains in place, administer initial dose <b>intravenously</b> through the catheter; administer as soon as possible and within 12 hours of extravasation; may readminister in 60 minutes if patient remains symptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Digital epinephrine injection (accidental), management (off-label use): </i>Local infiltration injection: <b>SUBQ:</b> 0.5 to 4.5 mg (diluted in 5 mL NS) divided into multiple SUBQ injections along the area of accidental injury; administer as soon as possible and within 12 hours of extravasation; may readminister in 60 minutes if patient remains symptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c73f50e3-c21c-49c5-a2d7-8e6fdd556645">Hypertensive crisis associated with catecholamine excess, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertensive crisis associated with catecholamine excess, treatment (eg, pheochromocytoma) (off-label use):</b></p>
<p style="text-indent:0em;margin-left:2em;">
<b>IV:</b> Initial: 5 mg bolus; repeat 5 mg bolus every 10 minutes as needed based on response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30354654','lexi-content-ref-21200059','lexi-content-ref-15931336']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30354654','lexi-content-ref-21200059','lexi-content-ref-15931336'])">Ref</a></span>). After initial bolus dosing, may consider a continuous infusion of 1 mg/hour titrated to BP response; maximum reported continuous infusion rate: ~50 mg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21200059','lexi-content-ref-15931336']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21200059','lexi-content-ref-15931336'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c981f95-40ee-4da5-a6b1-bb1e7e56ea8d">Perioperative hypertensive episodes associated with pheochromocytoma, prevention and management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Perioperative hypertensive episodes associated with pheochromocytoma, prevention and management:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Preoperative:</i>
<b>IM, IV:</b> 5 mg given 1 to 2 hours before surgery; repeat if needed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intraoperative:</i>
<b>IV:</b> Administer 5 mg as indicated to prevent or control paroxysms of hypertension, tachycardia, respiratory depression, seizure, or other effects associated with epinephrine intoxication resulting from tumor manipulation or other stressor (eg, intubation). May also consider an intraoperative continuous infusion of 1 to 6 <b>mcg</b>/kg/minute <b>or</b> intermittent boluses of 10 mg, as indicated, to manage BP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29195099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29195099'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="72e4444a-2201-425c-a035-81105dc2c1d6">Pheochromocytoma, diagnosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pheochromocytoma, diagnosis (phentolamine-blocking test):</b>
<b>Note:</b> The phentolamine-blocking test for the diagnosis of pheochromocytoma has largely been supplanted by the measurement of catecholamine concentrations and catecholamine metabolites (eg, metanephrine) in the plasma and urine; reserve phentolamine for cases when additional confirmation is necessary to determine diagnosis.</p>
<p style="text-indent:0em;margin-left:2em;">
<b>IV: </b>5 mg bolus; wait to administer until BP stabilizes after venipuncture, then record BP immediately after injection, then at 30-second intervals for first 3 minutes, followed by 60-second intervals for the next 7 minutes.</p>
<p style="text-indent:0em;margin-left:2em;">
<b>IM: </b>5 mg bolus; record BP every 5 minutes for 30 to 45 minutes.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fdd77cbe-dfa4-4ca2-9cdb-d3a6d7a1b274">Reversal of oral soft tissue anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of oral soft tissue (lip, tongue) anesthesia (OraVerse):</b>
<b>Note:</b> Dose is based upon the number of cartridges of local anesthetic administered.</p>
<p style="text-indent:0em;margin-left:2em;">Infiltration or block technique:</p>
<p style="text-indent:2em;margin-left:2em;">
<b>Submucosal oral injection:</b></p>
<p style="text-indent:2em;margin-left:4em;">0.1 mg if one-quarter cartridge of anesthesia was administered</p>
<p style="text-indent:2em;margin-left:4em;">0.2 mg if one-half cartridge of anesthesia was administered</p>
<p style="text-indent:2em;margin-left:4em;">0.4 mg if 1 cartridge of anesthesia was administered</p>
<p style="text-indent:2em;margin-left:4em;">0.8 mg if 2 cartridges of anesthesia were administered</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F58720854"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F58720852"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F58720891"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Bradycardia (OraVerse 2% to 4%), hypertension (OraVerse &lt;3%), cerebrovascular occlusion, hypotension, myocardial infarction</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Mouth pain (OraVerse ≤19%), headache (OraVerse 6%), paresthesia (OraVerse &lt;3%; mild, transient), cerebrovascular spasm</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Facial swelling (OraVerse &lt;3%), pruritus (OraVerse &lt;3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Diarrhea (OraVerse &lt;3%), upper abdominal pain (OraVerse &lt;3%), vomiting (OraVerse &lt;3%), nausea</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Pain at injection site (OraVerse 6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Jaw pain (OraVerse &lt;3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Postinjection pain (10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing and/or case reports: Cardiac arrhythmia, dizziness, flushing, nasal congestion, orthostatic hypotension, weakness</p></div>
<div class="block coi drugH1Div" id="F58720888"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to phentolamine, any component of the formulation, or related compounds; MI (or history of MI), coronary insufficiency, angina, or other evidence suggestive of coronary artery disease (excluding OraVerse).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Hypotension.</p></div>
<div class="block war drugH1Div" id="F58720889"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: MI, cerebrovascular spasm, and cerebrovascular occlusion have been reported following administration, usually associated with hypotensive episodes producing shock-like states. Tachycardia and cardiac arrhythmias may occur. Use with caution in patients with a history of cardiovascular disease. Discontinue if symptoms of angina occur or worsen.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: The use of phentolamine as a blocking agent in the screening of patients with hypertension has predominantly been replaced with urinary/biochemical assays; phentolamine use should be reserved for situations where additional confirmation is necessary and after risks associated with use have been considered.</p></div>
<div class="block foc drugH1Div" id="F58720933"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Solution, Injection, as mesylate [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">OraVerse: 0.4 mg/1.7 mL (1.7 mL) [contains edetate disodium; dental cartridge]</p>
<p style="text-indent:-2em;margin-left:2em;">Solution Reconstituted, Injection, as mesylate [preservative free]:</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: 5 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F58720873"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F58720936"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Phentolamine Mesylate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $501.60 - $587.95</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adip drugH1Div" id="F58720959"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Injection contains mannitol 25 mg/vial.</p></div>
<div class="block admp drugH1Div" id="F58720850"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Route varies with indication.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation treatment:</b> SUBQ: Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do NOT flush the line); remove needle/cannula; elevate extremity. Infiltrate area of extravasation with multiple small injections of a diluted phentolamine solution (as soon as possible but within 12 hours of extravasation); use 25- or 30-gauge <sup>1</sup>/<sub>2</sub>-inch needles; insert at a 15° angle, bevel up and change needle between each skin entry (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1720079','lexi-content-ref-3659173']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1720079','lexi-content-ref-3659173'])">Ref</a></span>) (see Management of Drug Extravasations). Apply dry warm compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-24420913'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pheochromocytoma diagnosis (Phentolamine block test): Note:</b> Patient should be supine throughout test, preferable in a quiet, dark room. Blood pressure should be monitored every 10 minutes for at least 30 minutes, delay phentolamine administration until after blood pressure is stable (at an untreated, hypertensive level).</p>
<p style="text-indent:-2em;margin-left:4em;">IM: After IM injection, monitor blood pressure every 5 minutes for 35 to 40 minutes. Blood pressure drops to target parameters - within 20 minutes are considered positive (see <b>Note</b>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Inject rapidly (after venous response to venipuncture has subsided); then monitor blood pressure immediately after injection, every 30 seconds for 3 minutes, then every minute for 7 minutes. Maximum response is generally achieved within 2 minutes; duration may last 15 to 30 minutes (although return to prior blood pressure may be sooner).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> A drop in blood pressure &gt;35 mm Hg systolic and &gt;25 mm Hg diastolic is considered a positive response. If blood pressure is elevated, unchanged, or decrease is &lt;35 mm Hg systolic and &lt;25 mm Hg diastolic, then response is negative. Confirm positive response with other diagnostic measure. Negative responses do not exclude a pheochromocytoma diagnosis, particularly in patients with paroxysmal hypertension where an incidence of false negatives is high.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pheochromocytoma-associated hypertensive episode:</b> IM, IV: Administer 1 to 2 hours prior to surgery and repeat during surgery (as rapid IV injection) if necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of oral soft tissue (lip, tongue) anesthesia (OraVerse</b>): Submucosal oral injection: Use the same location and dental technique employed for administration of the local anesthetic.</p></div>
<div class="block adm drugH1Div" id="F58720920"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Extravasation of vasopressors, management: Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Inject phentolamine 5 to 10 mg (diluted in 10 mL NS) divided into multiple SUBQ injections into extravasation site (as soon as possible but within 12 hours of extravasation); if IV catheter remains in place, administer initial dose <b>intravenously</b> through the catheter. Apply dry warm compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-4em;margin-left:6em;">For accidental digital epinephrine injection, inject phentolamine 0.5 to 4.5 mg (diluted in 5 mL NS) divided into multiple SUBQ injections along the area of accidental injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Pheochromocytoma diagnosis: Patient should be supine throughout test, preferable in a quiet, dark room. Blood pressure should be monitored every 10 minutes for at least 30 minutes, delay phentolamine administration until after blood pressure is stable (at an untreated, hypertensive level). A drop in blood pressure &gt;35 mm Hg (systolic) and &gt;25 mm Hg (diastolic) is considered a positive response. If blood pressure is elevated, unchanged, or decrease is &lt;35 mm Hg (systolic) and &lt;25 mm Hg (diastolic), then response is negative. Confirm positive response with other diagnostic measure. Negative responses do not exclude a pheochromocytoma diagnosis, particularly in patients with paroxysmal hypertension where an incidence of false negatives is high.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: After IM injection, monitor blood pressure every 5 minutes for 35 to 40 minutes. Blood pressure drops to above parameters within 20 minutes are considered positive.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Inject rapidly (after venous response to venipuncture has subsided); then monitor blood pressure immediately after injection, every 30 seconds for 3 minutes, then every minute for 7 minutes. Maximum response is generally achieved within 2 minutes; duration may last 15 to 30 minutes (although return to prior blood pressure may be sooner).</p>
<p style="text-indent:-2em;margin-left:2em;">Perioperative hypertensive episodes associated with pheochromocytoma, prevention and management: Administer IM or IV 1 to 2 hours prior to surgery and may repeat during surgery (with IV administration) if necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Reversal of oral soft tissue (lip, tongue) anesthesia (OraVerse): Submucosal oral injection: Use the same location and dental technique employed for administration of the local anesthetic.</p>
<p style="text-indent:-2em;margin-left:2em;">Hypertensive crisis associated with catecholamine excess, treatment (eg, pheochromocytoma) (off-label use): Administer as an IV bolus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30354654','lexi-content-ref-21200059','lexi-content-ref-15931336']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30354654','lexi-content-ref-21200059','lexi-content-ref-15931336'])">Ref</a></span>); may follow with a continuous IV infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21200059','lexi-content-ref-15931336']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21200059','lexi-content-ref-15931336'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F58720902"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Powder for injection: Store intact vials 20°C to 25°C (68°F to 77°F). Reconstituted solution should be used immediately after preparation (per manufacturer).</p>
<p style="text-indent:-2em;margin-left:2em;">Solution for injection (OraVerse): Store at 20°C to 25°C (68°F to 77°F); brief excursions permitted between 15°C to 30°C (59°F to 86°F). Protect from direct heat and light. Do not freeze.</p></div>
<div class="block usep drugH1Div" id="F58720957"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Powder for injection: Diagnosis of pheochromocytoma via the phentolamine-blocking test (see <b>Note</b>); prevention and management of hypertensive episodes associated with pheochromocytoma resulting from stress or manipulation during the perioperative period; prevention and treatment of dermal necrosis/sloughing after extravasation of norepinephrine (All indications: FDA approved in children and adults); has also been used for management of extravasations of other vasopressors including dobutamine, dopamine, epinephrine, and phenylephrine.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The phentolamine-blocking test for the diagnosis of pheochromocytoma has largely been supplanted by the measurement of catecholamine concentrations and catecholamine metabolites (eg, metanephrine) in the plasma and urine; reserve phentolamine for cases when additional confirmation is necessary to determine diagnosis.</p>
<p style="text-indent:-2em;margin-left:2em;">Dental cartridge (OraVerse): Reversal of soft tissue (ie, lip, tongue) anesthesia and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor (FDA approved in ages ≥3 years and adults)</p></div>
<div class="block mst drugH1Div" id="F58720866"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Phentolamine may be confused with phentermine, Ventolin</p>
<p style="text-indent:-2em;margin-left:4em;">Regitine may be confused with Reglan</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F58720897"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F58720894"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Alpha1-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers (Nonselective). Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilmenidine: Alpha1-Blockers may enhance the hypotensive effect of Rilmenidine. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F58720885"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in some oral animal reproduction studies. Diagnosing and treating pheochromocytoma is critical for favorable maternal and fetal outcomes (Schenker 1971; Schenker 1982).</p></div>
<div class="block mopp drugH1Div" id="F58720958"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, heart rate, orthostasis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Treatment of extravasation:</i> Site of extravasation, skin color, local perfusion.</p></div>
<div class="block pha drugH1Div" id="F58720907"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competitively blocks alpha-adrenergic receptors (nonselective) to produce brief antagonism of circulating epinephrine and norepinephrine to reduce hypertension caused by alpha effects of these catecholamines and minimizes tissue injury due to extravasation of these and other sympathomimetic vasoconstrictors (eg, dopamine, phenylephrine); also has a positive inotropic and chronotropic effect on the heart thought to be due to presynaptic alpha-2 receptor blockade which results in release of presynaptic norepinephrine (Hoffman 1980)</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">OraVerse: Causes vasodilation and increased blood flow in injection area via alpha-adrenergic blockade to accelerate reversal of soft tissue anesthesia</p></div>
<div class="block phk drugH1Div" id="F58720908"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: IM: 15 to 20 minutes; IV: 1 to 2 minutes (Chobanian 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: OraVerse: 10 to 20 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: IM: 30 to 45 minutes; IV: 10 to 30 minutes (Chobanian 2003)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV: 19 minutes; Submucosal injection: ~2 to 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~13% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F58720909"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: OraVerse C<sub>max</sub> ~3.5-fold higher in children weighing 15 to 30 kg compared with children weighing &gt;30 kg.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58885320"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Regitina</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Regitine</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Phentolamine mesylate</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Oraverse</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Regitine</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Regitin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Regitine</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Regitine</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Oraverse | Phentolamine mesylate</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Regitine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Beall.1">
<a name="Beall.1"></a>Beall V, Hall B, Mulholland JT, Gephart SM. Neonatal Extravasation. <i>NAINR</i>. 2013;13(4):189-195.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23928444">
<a name="23928444"></a>Boynes SG, Riley AE, Milbee S, Bastin MR, Price ME, Ladson A. Evaluating complications of local anesthesia administration and reversal with phentolamine mesylate in a portable pediatric dental clinic. <i>Gen Dent</i>. 2013;61(5):70-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/23928444/pubmed" id="23928444" target="_blank">23928444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12748199">
<a name="12748199"></a>Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. <i>JAMA</i>. 2003;289(19):2560-2572.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/12748199/pubmed" id="12748199" target="_blank">12748199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2805622">
<a name="2805622"></a>Cooper BE, "High-Dose Phentolamine for Extravasation of Pressors," <i>Clin Pharm</i>, 1989, 8(10):689.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/2805622/pubmed" id="2805622" target="_blank">2805622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19605999">
<a name="19605999"></a>Doellman D, Hadaway L, Bowe-Geddes LA, et al, “Infiltration and Extravasation: Update on Prevention and Management,” <i>J Infus Nurs</i>, 2009, 32(4):203-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/19605999/pubmed" id="19605999" target="_blank">19605999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8414723">
<a name="8414723"></a>Flemmer L, Chan JS. A pediatric protocol for management of extravasation injuries. <i>Pediatr Nurs. </i>1993;19(4):355-358, 424.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/8414723/pubmed" id="8414723" target="_blank">8414723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34158148">
<a name="34158148"></a>Hackenberg K, Kabir K, Müller A, Heydweiller A, Burger C, Welle K. Extravasation injuries of the limbs in neonates and children—development of a treatment algorithm. <i>Dtsch Arztebl Int</i>. 2021;118(33-34):547-554. doi:10.3238/arztebl.m2021.0220<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/34158148/pubmed" id="34158148" target="_blank">34158148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1720079">
<a name="1720079"></a>Hill JM. Phentolamine mesylate: the antidote for vasopressor extravasation. <i>Crit Care Nurse</i>. 1991;11(10):58-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/1720079/pubmed" id="1720079" target="_blank">1720079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-431702">
<a name="431702"></a>Hoff JV, Peatty PA, and Wade JL, “Dermal Necrosis From Dobutamine,” <i>N Engl J Med</i>, 1979, 300(22):1280.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/431702/pubmed" id="431702" target="_blank">431702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6246426">
<a name="6246426"></a>Hoffman BB, Lefkowitz RJ. Alpha-adrenergic receptor subtypes. <i>N Engl J Med</i>. 1980;302(25):1390-1396. doi:10.1056/NEJM198006193022504<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/6246426/pubmed" id="6246426" target="_blank">6246426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15192356">
<a name="15192356"></a>Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/15192356/pubmed" id="15192356" target="_blank">15192356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kiefer.2020">
<a name="Kiefer.2020"></a>Kiefer J, Mythen M, Roizen MF, and Fleisher LA. Anesthetic implications of concurrent diseases. In: Gropper MA, Miller R, eds. <i>Miller's Anesthesia</i>. 9th ed. Elsevier; 2020:chap 32.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6628223">
<a name="6628223"></a>MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm. </i>1983;17(10):713-717.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/6628223/pubmed" id="6628223" target="_blank">6628223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17565029">
<a name="17565029"></a>Marik PE and Varon J. Hypertensive Crises: challenges and management. <i>Chest</i>. 2007;131:1949-1962.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/17565029/pubmed" id="17565029" target="_blank">17565029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21200059">
<a name="21200059"></a>McMillian WD, Trombley BJ, Charash WE, et al. Phentolamine continuous infusion in a patient with pheochromocytoma. <i>Am J Health-Syst Pharm</i>. 2011;68:130-134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/21200059/pubmed" id="21200059" target="_blank">21200059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Miller.1">
<a name="Miller.1"></a>Miller RD, <i>Miller’s Anesthesia</i>, 7th ed, Philadelphia PA: Churchill Livingstone, 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10532013">
<a name="10532013"></a>Montgomery LA, Hanrahan K, Kottman K, et al. Guideline for I.V. infiltrations in pediatric patients. <i>Pediatr Nurs.</i> 1999;25(2):167-169, 173-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/10532013/pubmed" id="10532013" target="_blank">10532013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15931336">
<a name="15931336"></a>Myklejord DJ. Undiagnosed pheochromocytoma: the anesthesiologist nightmare. <i>Clin Med Res</i>. 2004;2(1):59-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/15931336/pubmed" id="15931336" target="_blank">15931336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-OraVerse.1">
<a name="OraVerse.1"></a>OraVerse (phentolamine mesylate) [prescribing information]. Louisville, CO: Septodont Inc; March 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park, MK, Salamat M. Appendix E: Drugs used in pediatric cardiology. In: <i>Park's Pediatric Cardiology for Practitioners</i>. 7th ed. Elsevier Health Sciences; 2021: 477-492.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956225">
<a name="20956225"></a>Peberdy MA, Callaway CW, Neumar RW, et al. Part 9: post cardiac arrest care: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation.</i> 2010;122(18)(suppl 3):768-786. doi:10.1161/CIRCULATIONAHA.110.971002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/20956225/pubmed" id="20956225" target="_blank">20956225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WestWard.1">
<a name="WestWard.1"></a>Phentolamine powder for solution [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; November 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WestWard.2">
<a name="WestWard.2"></a>Phentolamine powder for solution [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; September 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-32. doi:10.1002/phar.1396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19635770">
<a name="19635770"></a>Rhoney D and Peacock WF, “Intravenous Therapy for Hypertensive Emergencies, Part 1”, <i>Am J Health-Syst Pharm</i>, 2009, 66(15):1343-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/19635770/pubmed" id="19635770" target="_blank">19635770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5173093">
<a name="5173093"></a>Schenker JG and Chowers I, "Pheochromocytoma and Pregnancy. Review of 89 Cases," <i>Obstet Gynecol Surv</i>, 1971, 26(11):739-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/5173093/pubmed" id="5173093" target="_blank">5173093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6954937">
<a name="6954937"></a>Schenker JG and Granat M, "Phaeochromocytoma and Pregnancy - An Updated Appraisal," <i>Aust N Z J Obstet Gynaecol</i>, 1982, 22(1):1-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/6954937/pubmed" id="6954937" target="_blank">6954937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15728059">
<a name="15728059"></a>Schummer W, Schummer C, Bayer O, et al, “Extravasation Injury in the Perioperative Setting,” <i>Anesth Analg</i>, 2005, 100(3):722-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/15728059/pubmed" id="15728059" target="_blank">15728059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schure.1">
<a name="Schure.1"></a>Schure AY, DiNardo JA. Cardiac physiology and pharmacology. In: Coté CJ, Lerman J, Anderson B, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 6th ed. Elsevier; 2019:424-457.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3659173">
<a name="3659173"></a>Siwy BK and Sadove AM, "Acute Management of Dopamine Infiltration Injury With Regitine," <i>Plast Reconstr Surg</i>, 1987, 80(4):610-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/3659173/pubmed" id="3659173" target="_blank">3659173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11536027">
<a name="11536027"></a>Subhani M, Sridhar S, and DeCristofaro JD, "Phentolamine Use in a Neonate for the Prevention of Dermal Necrosis Caused by Dopamine: A Case Report," <i>J Perinatol</i>, 2001, 21(5):324-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/11536027/pubmed" id="11536027" target="_blank">11536027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18069429">
<a name="18069429"></a>Thigpen JL, "Peripheral Intravenous Extravasation: Nursing Procedure for Initial Treatment,"<i> Neonatal Netw</i>, 2007, 26(6):379-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/18069429/pubmed" id="18069429" target="_blank">18069429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14727943">
<a name="14727943"></a>Tuncel M and Ram VC, “Hypertensive Emergencies. Etiology and Management,” <i>Am J Cardiovasc Drugs</i>, 2003, 3(1):21-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/14727943/pubmed" id="14727943" target="_blank">14727943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published online ahead of print on November 13, 2017.]. <i>Hypertension</i>. 2017. doi:10.1161/HYP.0000000000000065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30354654">
<a name="30354654"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i>. 2018;138(17):e484-e594. doi:10.1161/CIR.0000000000000596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/30354654/pubmed" id="30354654" target="_blank">30354654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29195099">
<a name="29195099"></a>Yu M, Han C, Zhou Q, Liu C, Ding Z. Clinical effects of prophylactic use of phentolamine in patients undergoing pheochromocytoma surgery. <i>J Clin Anesth</i>. 2018;44:119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentolamine-systemic-pediatric-drug-information/abstract-text/29195099/pubmed" id="29195099" target="_blank">29195099</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 142992 Version 5.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
